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secutive patients undergoing ablative BMT at OHSU without ABX
prophylaxis from 2001 to 2002. Results: The median duration of
MOXI prophylaxis was 77 days (range, 7–87 days). Five patients
had dose interruptions, 4 due to nausea associated with GVHD,
and 1 patient withdrew from the study. Three patients had dose
interruptions during empiric ABX therapy for possible bacterial
infection. Overall, MOXI was well tolerated in this patient popu-
lation, with 5 episodes of grade 3/4 toxicity possibly related to
study drug (2 orthostatic hypotension in 1 patient, 2 nausea, and 1
hypertension). Five patients had episodes of transaminitis that were
unlikely to be due to the study medication and that responded to
discontinuation of azole antifungal therapy (4) or to treatment of
liver GVHD (1). No cardiac arrhythmias were observed. Com-
pared with historic controls, a marked decrease in postengraftment
bacterial infections was observed. In the control cohort, 16 patients
experienced 17 episodes of Gram-negative infections and 22 pa-
tients had 25 episodes of symptomatic Gram-positive infections
during the postengraftment phase without prophylaxis. In contrast
with MOXI prophylaxis, 2 patients experienced 3 Gram-negative
infections (2 test, P  .079), 1 patient had an anaerobic infection,
and 7 patients had 9 symptomatic Gram-positive infections. Two
breakthrough bacteremias with Streptococcus viridans occurred and
were treated successfully. ABX MICs of Gram-negative isolates
showed P. putida sensitive to MOXI and C. freundii resistant, both
without drug efﬂux. Conclusions: Prophylactic MOXI dosed
throughout the postengraftment phase has been well tolerated,
safe, and associated with fewer bacterial infections compared to
historic controls. The efﬁcacy of this prophylaxis strategy will be
determined in a planned randomized, placebo-controlled trial.
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HEMATOLOGIC EFFECTS OF LINEZOLID IN FEBRILE NEUTROPENIC
PATIENTS
Jaksic, B.1; Hartman, C.S.2; Leonard, L.B.2; Tack, K.J.2 1. Merkur
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Linezolid (LZD) is an oxazolidinone antibacterial effective for
the treatment of infections caused by Gram-positive pathogens
including methicillin-resistant Staphylococcus spp., glycopeptide-re-
sistant Enterococcus spp., and multi-drug resistant Streptococcus pneu-
moniae. Hematopoietic suppression is a side effect associated with
several classes of antibiotics. Linezolid has been associated with
reversible thrombocytopenia and anemia, predominately in pa-
tients with serious infections treated beyond the recommended 28
days. In patients receiving myelosuppressive chemotherapy, addi-
tional bone marrow suppression may have clinical signiﬁcance.
The effect of LZD on platelet (PLT) and white blood cell (WBC)
recovery and on hemoglobin (HGB) levels was assessed compared
with vancomycin (VAN) in febrile neutropenic oncology patients.
Methods: LZD was compared with VAN in a randomized, dou-
ble-blind, multicenter trial. Oncology patients with febrile neutro-
penia (absolute neutrophil count  500/mm3) and a proven or
suspected Gram-positive infection received LZD (600 mg) or
VAN (1 g) intravenously every 2 hours for 10–28 days. Laboratory
values were checked at deﬁned times, including end-of-therapy
(EOT) and follow-up (FU), 7 days posttherapy. Results: 605
patients were treated (304 LZD, 301 VAN); treatment groups were
similar with respect to demographics, comorbidities, severity and
type of illness, and duration of neutropenia. Hematologic/lym-
phatic cancers were the most common in both groups (95.4%
LZD; 93.7% VAN). Average duration of treatment was similar
between groups (LZD, 11.4 days; VAN, 11.5 days). Overall mor-
tality rate at 16 days posttherapy was 5.6% for LZD versus 7.6%
for VAN (P  .31). Overall clinical success rates at FU were
comparable between LZD and VAN (57.0% vs 52.9%; P  .32).
Mean (	SD) values for HGB, PLT, WBC, and ANC at baseline
(BL), EOT, and FU were as follows. Incidence of complications
related to bleeding was similar in the groups (34 reports for LZD
and 38 for VAN) and were reported for 1% of patients in either
group with the exception of epistaxis (3.3% for LZD, 5.0% for
VAN) and petechiae (1.7% for LZD, 1.0% for VAN). Conclu-
sions: LZD did not suppress recovery of PLT counts when com-
pared with VAN and did not have an effect on HGB or WBCs.
Treatment did not result in increased incidence of events related to
bleeding. LZD is a reasonable therapeutic option for the treatment
of febrile neutropenic oncology patients with proven or suspected
Gram-positive infections.
BL EOT* FU*
HGB LZD 8.8 (1.6) 9.4 (1.5) 10.0 (1.6)
g/dL VAN 8.8 (1.6) 9.3 (1.5) 10.0 (1.7)
PLT LZD 28 (31) 75 (116) 141 (148)
K/mm3 VAN 32 (54) 75 (99) 150 (165)
WBC LZD 0.77 (2.4) 3.85 (5.2) 4.79 (5.2)
K/mm3 VAN 1.18 (9.0) 4.39 (5.5) 5.12 (6.5)
ANC LZD 0.12 (0.34) 2.48 (4.14) 2.99 (4.41)
K/mm3 VAN 0.11 (0.29) 2.79 (4.36) 2.93 (3.59)
*Statistical signiﬁcance not observed between groups for mean
change from baseline
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Pulmonary toxicity is a major complication of HSCT and the
leading cause of early post-HSCT mortality. Various lung insults
have been implicated in the pathogenesis of post-HSCT lung
injury in association with speciﬁc therapies or patient populations.
Such lung insults are thought to act additively, whereby several
insults together produce injury not anticipated with any one alone.
We have developed a dual hit murine model of lung injury after
syngeneic HSCT in which subclinical infection with Pneumocystis
carinii sp. muris (Pc) produces an inﬂammatory response that sen-
sitizes the lung to the damaging effects of TBI. Mice infected with
Pc 7 days before receiving TBI and a syngeneic HSCT developed
a severe interstitial pneumonitis that was not seen in animals who
were treated with either Pc infection or TBI alone. Pulmonary
dysfunction was evident as early as 12 days post-HSCT and was
marked by signiﬁcant weight loss, increased respiratory rate, and
decreased dynamic lung compliance. The resultant inﬂammation
was characterized by large numbers of eosinophils and lympho-
cytes in the BALF, with a progressive inﬂux of lymphocytes pre-
dominated by CD8 T cells. In vivo depletion of both CD4 and
CD8 T cells abrogated the pulmonary compromise and inﬂam-
mation, suggesting that this process is T-cell dependent. The lung
injury observed in this model was not attributable to direct damage
caused by Pc, because average Pc lung burdens were actually 1 log
higher in the T-cell-depleted animals, who exhibited no pulmo-
nary compromise. Finally, the severity of disease appears to be
associated with increased expression of TNF-, as well as other
immune-modulating cytokines, such as IFN-. We hypothesize
that TNF- is central in mediating the observed synergy of these
detrimental lung effects and that T cells are critical in driving the
inﬂammatory response that results in bystander lung injury.
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